A standardized assay in 96-well microtiter plates for syncytium-inducing (SI) human immunodeficiency virus type 1 phenotype detection using MT-2 cells has been developed. SI variants were found in 67% of the patients with advanced human immunodeficiency virus disease. The occurrence of the SI phenotype increased with lower CD4+ counts. There was no association between p24 antigenemia and the SI phenotype.
Syncytium-inducing (SI) human immunodeficiency virus type 1 (HIV-1) variants have been shown to be clinically significant in the pathogenesis of HIV-1 infection (1-3, 10, 12, 18) . The ability of HIV-1 isolates to produce cytopathic effects in a human T-cell leukemia virus type I-transformed lymphoblastoid cell line (MT-2 cells) has been shown to be sensitive to and specific for SI capacity (5, 11) . Within a single HIVpositive individual, a heterogenous population of SI and non-SI (NSI) HIV-1 can be detected, and these virus populations shift over time (4, 13) . A shift from a predominately monocytotropic NSI HIV-1 variant population to a T-cell tropic SI population has been associated with progression of HIV-1 disease (16) . While SI viruses have been detected at all stages of HIV-1 infection, they are more commonly found among individuals with advanced disease (15, 17, 19) . The presence of the SI phenotype is also correlated with accelerated CD4+ count declines (2, 10, 12, 14 a Columns A to G refer to experimental results as depicted in Fig. 1 . +, p24 antigen detected after cocultivation; numbers, day after culture on which SI cytopathic effect was first observed; ND, not done. patient-derived specimens. PBMC from 21 HIV-positive individuals were processed as depicted in Fig. 1 . The data were analyzed by using the result obtained by cocultivation of fresh PBMC with MT-2 cells as the reference standard (Fig. 1,  column B) . This standard was chosen because it represents the viral phenotype before specimen handling (HIV-1 amplification and/or freezing) and was the assay originally described by Koot and coworkers (11) . Results using virus stocks (Table 2 , columns C and F) from fresh PBMC cocultures most closely agreed with the reference standard. The worst agreement was observed when PBMC were initially cryopreserved and then processed in culture ( Table 2 , columns E and G). Virus stock specimens, when SI, were positive earlier than PBMC specimens from the same patients ( Table 2 ). The results indicated that the use of virus stocks in the microtiter assay format accurately reflected the presence of the SI phenotype in the patient.
Association of viral phenotype with CD4+ count and p24 antigenemia. Baseline virus isolates (n = 255) from subjects enrolled in the AIDS Clinical Trial Group 116B/117 were assayed for the SI phenotype (9) . Enrollees in the AIDS Clinical Trial Group 116B/117 had a minimum of 16 In conclusion, the standardized microtiter assay for the detection of SI variants presented herein provides a uniform and inexpensive method for testing clinical HIV-1 isolates. A standardized assay is essential for use in multicenter studies. While it does not appear necessary to determine the titers of all HIV-1 virus stocks for use in the assay, false negative findings (interpreted as NSI) can result from the use of a noninfectious virus supernatant. In cases in which the infectivity of the virus stock is not known, a control infection of PBMC is appropriate to confirm an NSI interpretation.
